Table 2: Primary and secondary outcomesa.
Receipt of bone modifying agents within 180, 90, and 365 days of diagnosis after initiation of CRPC-defining treatment for all patients and stratified by presence of bone metastases.
| Characteristic | Overall (%) | Bone metastasis (%) | No bone metastasis (%) | |
|---|---|---|---|---|
| Total | 1292 | 1034 | 258 | |
| 180 days | Any BMA | 761 (59%) | 705 (68%) | 56 (22%) |
| Denosumab | 430 (33%) | 395 (38%) | 35 (14%) | |
| Zoledronic acid | 331 (26%) | 310 (30%) | 21 (8%) | |
| Secondary outcomes | ||||
| 90 days | Any BMA | 703 (54%) | 662 (64%) | 41 (16%) |
| Denosumab | 393 (30%) | 369 (36%) | 24 (9%) | |
| Zoledronic acid | 310 (24%) | 293 (28%) | 17 (7%) | |
| 365 days | Any BMA | 810 (63%) | 742 (72%) | 68 (26%) |
| Denosumab | 469 (36%) | 425 (41%) | 44 (17%) | |
| Zoledronic acid | 341 (26%) | 317 (31%) | 24 (9%) | |
a
BMA, bone modifying agent.